Commentary Open Access
Volume 4 | Issue 1 | DOI: https://doi.org/10.46439/cardiology.4.028
Omecamtiv mecarbil for heart failure: Unpacking the latest systematic review and meta-analysis
Ramzi Ibrahim 1,*
- 1Department of Medicine, University of Arizona Tucson, Tucson, Arizona
Corresponding Author
Ramzi Ibrahim, ramziibrahim@arizona.edu
Received Date: April 16, 2023
Accepted Date: May 16, 2024
Ibrahim R. Omecamtiv mecarbil for heart failure: Unpacking the latest systematic review and metaanalysis. Int J Cardiol Cardiovasc Dis. 2024;4(1)1-2.
Copyright: © 2024 Ibrahim R. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Keywords
Omecamtiv mecarbil, Heart failure, FDA
Recommended Articles
Retrospective evaluation of heart failure verification and relation to readmission and all-cause mortality in a community-based cohort
The use of administrative databases to determine predictors for heart failure (HF) readmission, cardiovascular, or all-cause mortality (ACM) requires HF coding that is verifiable. It is assumed that administrative databases have HF verified via coders based on physician documentation and additional criteria.
Shared care left ventricular assist device site to implant center: the next step in advanced heart failure treatment and an essential part of healthcare worldwide
Heart failure is a growing pandemic affecting approximately 6.2 million people in the US and 15 million people worldwide. Given its prevalence, high morbidity and mortality, and financial burden on our healthcare system, establishing strategies focused on improving therapeutic outcomes and prognosis has become a major priority.
Omecamtiv mecarbil for heart failure: Unpacking the latest systematic review and meta-analysis
In February 2023, a systematic review and meta-analysis of six randomized controlled trials (RCTs) with a total of 9,596 patients assessed the effectiveness and safety of omecamtiv mecarbil (OM) versus placebo in patients with heart failure with reduced left ventricular ejection fraction (HFrEF) [1].